Canada - anglais - Health Canada

pfizer canada ulc - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - antineoplastic chemotherapy - treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic and meningeal leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemia. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides. high dose therapy - the use of very high doses is made possible by vials for injection containing 500 mg and 1000 mg (see precautions). diseases treated with these doses administered in the form of single-drug or combination therapy, include osteogenic sarcoma, acute leukaemia, bronchogenic carcinoma and epidermoid carcinoma of the head and neck. psoriasis chemotherapy - because of the high risk attending to its use, methotrexate injection is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may be used to treat psoriasis and severe rheumatoid arthritis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; sodium chloride - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may also be used to treat severe psoriasis and severe rheumatoid arthritis.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - indicated for treatment of solid tumours and hematologic malignancies: - breast cancer - cervical cancer - epidermoid cancers (squamous cell carcinoma) of head and neck - osteosarcoma - choriocarcinoma (gestational trophoblastic neoplasm) - lung cancer - bladder cancer (locally advanced/metastatic) - acute lymphoblastic leukemia - meningeal leukemia or lymphoma - non-hodgkin?s lymphoma - histiocytic and lymphatic lymphoma, burkitt?s lymphoma - ovarian carcinoma - testicular carcinoma - mycosis fungoides (cutaneous t cell lymphoma) - chorioadenoma destruens - hydatidiform mole

Irlande - anglais - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - methotrexate disodium - oral solution - 2 mg/ml - methotrexate - antineoplastic and immunomodulating agents, antimetabolites, folic acid analogues - it is indicated in the following oncological indications: the maintenance treatment of acute lymphocytic leukaemia (all) in children and adults; the treatment of malignant trophoblastic tumours and for the treatment of severe active rheumatoid arthritis in adults and the treatment of severe forms of psoriasis vulgaris including chronic plaque psoriasis, erythrodermic psoriasis, psoriatic arthritis and pustular psoriasis which are not responsive to other conventional therapies such as phototherapy, puva and retinoids.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 100 mg/ml - injection, solution - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - methotrexate, quantity: 50 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - antineoplastic chemotherapy - methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer, gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole. methotrexate may be used in combination with other chemotherapeutic agents for the palliative treatment of acute leukaemias, particularly acute lymphoblastic leukaemia. it may also be used in the treatment of burkitt's lymphoma, advanced stages (iii and iv, peters' staging system) of lymphosarcoma, especially in children, and in advanced cases of mycosis fungoides. high dose therapy - in high-dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic carcinoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy. psoriasis chemotherapy (see warning box) - methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after the diagnosis has been definitely established, as by biopsy and/or after dermatologic consultation.

Canada - anglais - Health Canada

sandoz canada incorporated - methotrexate (methotrexate sodium) - solution - 25mg - methotrexate (methotrexate sodium) 25mg - antineoplastic agents

Australie - anglais - Department of Health (Therapeutic Goods Administration)

pfizer (perth) pty ltd - methotrexate, quantity: 25 mg/ml - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - latam (cri, dom, slv, gtm, hnd, nic, pan): methotrexate is a cytotoxic drug used for antineoplastic chemotherapy and in certain nonmalignant conditions. oncological indications: methotrexate is indicated for the treatment of the following solid tumors and hematologic malignancies: ? choriocarcinoma (gestational trophoblastic neoplasm) ? chorioadenoma destruens ? hydatidiform mole ? acute lymphoblastic leukemia ? breast cancer ? cervical cancer ? ovarian carcinoma ? testicular carcinoma ? bladder cancer (locally advanced/metastic) ? epidermoid cancers (squamous cell carcinoma) of head and neck ? mycosis fungoides (cutaneous t cell lymphoma) ? lung cancer ? non-hodgkin?s lymphoma ? meningeal lymphoma ? histiocytic and lymphatic lymphoma, burkitt?s lymphoma ? osteosarcoma ? meningeal leukemia other diseases: ? psoriasis ? rheumatoid arthritis including polyarticular-course juvenile rheumatoid arthritis (jra) serbia: ? breast cancer, ? gestational choriocarcinoma ? chorioadenoma destruens ? hydatidiform mole. ? acute and subacute lymphocytic and meningeal leukaemia. ? acute lymphoblastic leukaemias. ? advanced stages (iii and iv, peters staging system) of lymphosarcoma, ? mycosis fungoides. ? osteogenic sarcoma ? acute leukaemia ? bronchogenic carcinoma ? epidermoid carcinoma of the head and neck. ? psoriasis